½ÃÀ庸°í¼­
»óǰÄÚµå
1561560

¹ÙÀÌ¿À¹ðÅ© ½ÃÀå º¸°í¼­ : °Ëü À¯Çüº°, ¹ÙÀÌ¿À¹ðÅ© À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°(2024-2032³â)

Biobanking Market Report by Specimen Type, Biobank Type, Application, End-User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 148 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¹ÙÀÌ¿À¹ðÅ© ½ÃÀå ±Ô¸ð´Â 2023³â 610¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. IMARC GroupÀº ÇâÈÄ ½ÃÀåÀÌ 2032³â±îÁö 991¾ï ´Þ·¯¿¡ À̸¦ Àü¸ÁÀ̸ç, 2024³âºÎÅÍ 2032³â±îÁö 5.4%ÀÇ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. À¯Àüü ¿¬±¸ Ȱµ¿ Áõ°¡, ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, °¡»ó ¹ÙÀÌ¿À ¹ðÅ©¿¡ ´ëÇÑ °ü½É Áõ°¡´Â ½ÃÀåÀ» °ßÀÎÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù.

¹ÙÀÌ¿À¹ðÅ©´Â ü¾×°ú Á¶Á÷ÀÇ »ùÇÃÀ» ¼öÁý, ÀúÀå, ÁÖ¼®À» ´Þ°í °Ç°­°ú Áúº´¿¡ ´ëÇÑ ÀÌÇØ¸¦ ³ôÀÌ´Â ¿¬±¸¸¦ À§ÇØ Àç¹èÆ÷ÇÏ´Â °úÁ¤À» ¸»ÇÕ´Ï´Ù. ¹ÙÀÌ¿À¹ðÅ©´Â »ùÇÃÀÇ ½Å·ÚÇÒ ¼ö ÀÖ´Â Çãºê·Î °íǰÁú »ùÇà Ǯ°ú °ü·Ã µ¥ÀÌÅÍ¿¡ ´ëÇÑ ¾×¼¼½º¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¼ö¸¹Àº Áúº´ÀÇ Áø´Ü°ú ÀǾàǰ Á¦Á¶¿¡ ÇʼöÀûÀÔ´Ï´Ù. È¿°úÀûÀÎ ¹ÙÀÌ¿À¸¶Ä¿ ½Äº°ÀÌ Áúº´ÀÇ Áø´Ü°ú ¿¹ÈÄ¿¡ ÇʼöÀûÀÎ °³ÀÎÈ­µÈ ÀÇ·á Á¢±Ù¹ýÀ» °³¼±ÇÏ´Â ±â¹ÝÀ» Á¦°øÇÕ´Ï´Ù. ¼ö¸¹Àº ¿¬±¸¿Í ´Ù¾çÇÑ Á¶»ç¿¡¼­ Á¦°ø¾÷ü¿Í ¿¬±¸ÀÚÀÇ Áß°³¿ªÀ» ¼öÇàÇÕ´Ï´Ù. °íǰÁúÀÇ °ü¸®¸¦ ½Ç½ÃÇØ, ´Ù¾çÇÑ ½ÇÇèÀÇ ÀçÇö¼ºÀÇ Çâ»óÀ» Áö¿øÇÕ´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿À »ùÇÃÀ» ÅëÇØ »ý¼ºµÈ µ¥ÀÌÅÍ´Â ÀÇ·á ½Ã½ºÅÛÀÇ µðÁöÅÐ º¯È­¿¡ ÇʼöÀûÀÔ´Ï´Ù. ±× °á°ú, ¹ÙÀÌ¿À¹ðÅ©´Â ¾à¹°°ú ¹ÙÀÌ¿À¸¶Ä¿ÀÇ °³¹ß, Ä¡·á¸¦ À§ÇÑ ÀÓ»ó Äɾî, ÃÖÁ¾ °á°ú¿¡ ´ëÇÑ ¾à¹°ÀÇ È¿°ú¸¦ ¸ð´ÏÅ͸µÇÏ´Â ÀÓ»ó½ÃÇè¿¡¼­ Àü ¼¼°èÀûÀ¸·Î ³Î¸® Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿À¹ðÅ© ½ÃÀå µ¿Çâ :

ÇöÀç À¯Àüü ¿¬±¸ Ȱµ¿ Áõ°¡·Î ÀÎÇÑ ¹ÙÀÌ¿À ¹ðÅ· ¼ö¿ä Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» Áö¿øÇÏ´Â Áß¿äÇÑ ¿ä¼Ò Áß ÇϳªÀÔ´Ï´Ù. ÀÌ ¿Ü¿¡µµ ¹ÙÀÌ¿À¹ðÅ©ÀÇ ¼ö´Â ¼¼°èÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, »ý¹°ÀÇÇÐ ¿¬±¸¿¡ ÀÇÇØ »ý¼ºµÈ µ¥ÀÌÅÍÀÇ ÀçÇö¼º°ú Àǹ̸¦ ³ôÀÏ ¼ö Àֱ⠶§¹®¿¡ ½ÃÀå Àü¸ÁÀº ¹à½À´Ï´Ù. ¶ÇÇÑ ¼¼°è ´ëÁßµé »çÀÌ¿¡¼­ ´ç´¢º´, °íÇ÷¾Ð, ¾Ï, ½ÉÀå ¹ßÀÛ, È£Èí±â Áúȯ µî ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ »ó½ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â º´¿øÃ¼¸¦ È¿°úÀûÀ¸·Î È®ÀÎÇÒ ¼ö ÀÖ´Â Áø´Ü¹ýÀ» °³¹ßÇϱâ À§ÇÑ ¹ÙÀÌ¿À¹ðÅ©¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ´õºÒ¾î ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. À̿ʹ º°µµ·Î Àç»ýÀÇ·á, °³ÀÎÈ­ÀÇ·á, ¾Ï À¯Àüü ¿¬±¸ µîÀÇ Ã·´Ü¿ä¹ý¿¡ ´ëÇÑ ÁöÃâÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ¾÷°è ÅõÀÚÀÚ¿¡°Ô À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, À¯ÀüÀÚ °Ë»ç ºÐ¼®À» °³¹ßÇϱâ À§ÇØ ÀÓ»ó ¿¬±¸½Ã¼³¿¡¼­ »ý¹° »ùÇà ¼ö¿ä Áõ°¡°¡ ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Ã°£Àû Á¦¾àÀ» ÃÖ¼ÒÈ­Çϰí, ³ôÀº ¼öÀÍÀ» ¿Ã¸®°í, ¿¬±¸ÀÚ°¡ ¿øÈ°ÇÏ°Ô Á¶»ç¸¦ ½Ç½ÃÇÒ ¼ö ÀÖ´Â °¡»ó ¹ÙÀÌ¿À¹ðÅ©¿¡ ´ëÇÑ ÁÖ¸ñ Áõ°¡°¡ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷Àº °¡½Ã¼ºÀ» È®º¸ÇÏ°í °í°´¿¡°Ô Á¦°øÇÏ´Â ¼­ºñ½º ǰÁúÀ» Çâ»ó½ÃŰ´Â ¹ÙÀÌ¿À¹ðÅ© ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼ÇÀ» µµÀÔÇÏ¿© ½ÃÀå ¼ºÀåÀ» °­È­Çϰí ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

  • 2023³â ¼¼°èÀÇ ¹ÙÀÌ¿À¹ðÅ© ½ÃÀå ±Ô¸ð´Â?
  • 2024³âºÎÅÍ 2032³â±îÁö ¼¼°è ¹ÙÀÌ¿À¹ðÅ© ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • ¼¼°èÀÇ ¹ÙÀÌ¿À¹ðÅ© ½ÃÀåÀ» °ßÀÎÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
  • ¼¼°èÀÇ ¹ÙÀÌ¿À¹ðÅ© ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâÀº?
  • ¼¼°è ¹ÙÀÌ¿À¹ðÅ© ½ÃÀåÀÇ °Ëü À¯Çüº° ³»¿ªÀº?
  • ¼¼°è ¹ÙÀÌ¿À¹ðÅ© ½ÃÀåÀÇ ¹ÙÀÌ¿À¹ðÅ© À¯Çüº° ³»¿ªÀº?
  • ¼¼°è ¹ÙÀÌ¿À¹ðÅ© ½ÃÀåÀÇ ¿ëµµº° ³»¿ªÀº?
  • ¼¼°è ¹ÙÀÌ¿À¹ðÅ© ½ÃÀåÀÇ ÃÖÁ¾ »ç¿ëÀÚº° ³»¿ªÀº?
  • ¼¼°è ¹ÙÀÌ¿À ¹ðÅ· ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
  • ¼¼°è ¹ÙÀÌ¿À¹ðÅ© ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§ ¹× Á¶»ç ¹æ¹ý

  • Á¶»çÀÇ ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­¹®

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ¹ÙÀÌ¿À¹ðÅ© ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : °Ëü À¯Çüº°

  • Ç÷¾× Á¦Ç°
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • °íü Á¶Á÷
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¼¼Æ÷ÁÖ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ÇÙ»ê
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ³»¿ª : ¹ÙÀÌ¿À¹ðÅ© À¯Çüº°

  • Áý´Ü ±â¹ÝÀÇ ¹ÙÀÌ¿À¹ðÅ©
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Áúº´ ÁöÇâ ¹ÙÀÌ¿À¹ðÅ©
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ³»¿ª : ¿ëµµº°

  • Ä¡·áÁ¦
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Á¶»ç
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾ »ç¿ëÀÚº°

  • Çмú±â°ü
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ³»¿ª : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦11Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • °æÀïµµ
  • ½Å±Ô ÁøÀÔ¾÷ÀÚÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Brooks Automation Inc.
    • Bay Biosciences LLC
    • Boca Biolistics
    • Ctibiotech
    • Cureline Inc.
    • Firalis
    • Greiner Bio-One International GmbH
    • Hamilton Company
    • Merck KGaA
    • ProteoGenex Inc.
    • Thermo Fisher Scientific Inc.
    • VWR Corporation(Avantor Inc.)
AJY 24.10.08

The global biobanking market size reached US$ 61.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 99.1 Billion by 2032, exhibiting a growth rate (CAGR) of 5.4% during 2024-2032. The rising number of genomic research activities, increasing prevalence of chronic diseases, and rising focus on virtual biobank represent some of the key factors driving the market.

Biobanking refers to the process wherein samples of bodily fluid or tissue are collected, stored, annotated, and redistributed for research to improve the understanding of health and disease. It is a reliable hub of samples and enables access to a pool of high-quality samples and associated data. It is essential for the diagnosis and production of medicines for numerous disorders. It provides a basis for improving personalized medical approaches wherein effective biomarker identification is vital for disease diagnosis and prognosis. It serves as a mediator between donor and researcher for numerous research and different studies. It has high-quality control and assists in improving the reproducibility of various experiments. It also offers data generated through biosamples that is crucial for the digital transformation of health systems. As a result, biobanking is widely utilized in drug and biomarker development, clinical care for therapy, and clinical trials monitoring for the effects of drugs on eventual outcomes across the globe.

Biobanking Market Trends:

At present, the rising demand for biobanking due to the increasing number of genomic research activities represents one of the key factors supporting the growth of the market. Besides this, the growing number of biobanks across the globe, due to its potential to enhance the reproductivity and meaning of data generated by biomedical research, is offering a positive market outlook. Additionally, there is a rise in the prevalence of chronic diseases, such as diabetes, hypertension, cancer, heart attack, and respiratory disorders, among the masses around the world. This, coupled with the increasing demand for biobanking to develop diagnostics that can effectively identify pathogens, is propelling the growth of the market. Apart from this, the rising expenditure in advanced therapies, such as regenerative medicine, personalized medicine, and cancer genomic studies, is offering lucrative growth opportunities to industry investors. Moreover, the increasing demand for biospecimens from clinical labs to develop assays for genetic testing is positively influencing the market. In addition, the growing focus on virtual biobank that minimizes time constraints, generates high revenue, and allows researchers to conduct the research smoothly is contributing to the growth of the market. Furthermore, key players are introducing a biobank software solution that assists in gaining visibility and improving the quality of the service provided to customers, which is strengthening the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global biobanking market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on specimen type, biobank type, application and end user.

Specimen Type Insights:

  • Blood Products
  • Solid Tissue
  • Cell Lines
  • Nucleic Acid
  • Others

The report has provided a detailed breakup and analysis of the biobanking market based on the specimen type. This includes blood products, solid tissue, cell lines, nucleic acid, and others. According to the report, blood products represented the largest segment.

Biobank Type Insights:

  • Population-based Biobanks
  • Disease-oriented Biobanks

A detailed breakup and analysis of the biobanking market based on the biobank type has also been provided in the report. This includes population-based biobanks and disease-oriented biobanks. According to the report, disease-oriented biobanks accounted for the largest market share.

Application Insights:

  • Therapeutics
  • Research

A detailed breakup and analysis of the biobanking market based on the application has also been provided in the report. This includes therapeutics and research. According to the report, research accounted for the largest market share.

End-User Insights:

  • Academic Institutions
  • Pharma and Biotech Companies

A detailed breakup and analysis of the biobanking market based on the end-user has also been provided in the report. This includes academic institutions and pharma and biotech companies. According to the report, academic institutions accounted for the largest market share.

Regional Insights:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Europe was the largest market for biobanking. Some of the factors driving the Europe biobanking market included rising advancements in the stem cell and regenerative medicine research, increasing awareness about stem cell therapies, high demand for automated alarm monitoring devices, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global biobanking market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Brooks Automation Inc., Bay Biosciences LLC, Boca Biolistics, Ctibiotech, Cureline Inc., Firalis, Greiner Bio-One International GmbH, Hamilton Company, Merck KGaA, ProteoGenex Inc., Thermo Fisher Scientific Inc., VWR Corporation (Avantor Inc.), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. What was the size of the global biobanking market in 2023?
  • 2. What is the expected growth rate of the global biobanking market during 2024-2032?
  • 3. What are the key factors driving the global biobanking market?
  • 4. What has been the impact of COVID-19 on the global biobanking market?
  • 5. What is the breakup of the global biobanking market based on the specimen type?
  • 6. What is the breakup of the global biobanking market based on the biobank type?
  • 7. What is the breakup of the global biobanking market based on the application?
  • 8. What is the breakup of the global biobanking market based on the end user?
  • 9. What are the key regions in the global biobanking market?
  • 10. Who are the key players/companies in the global biobanking market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Biobanking Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Specimen Type

  • 6.1 Blood Products
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Solid Tissue
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cell Lines
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Nucleic Acid
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Biobank Type

  • 7.1 Population-based Biobanks
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Disease-oriented Biobanks
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Therapeutics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Academic Institutions
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Pharma and Biotech Companies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Brooks Automation Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 Bay Biosciences LLC
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Boca Biolistics
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Ctibiotech
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 Cureline Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Firalis
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Greiner Bio-One International GmbH
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 Hamilton Company
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Merck KGaA
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 ProteoGenex Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 Thermo Fisher Scientific Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 VWR Corporation (Avantor Inc.)
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦